Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06561178 | Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401) | recruiting | — | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) | recruiting | N/A | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 7 |
| Aug 26, 2024 |
| clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04481256 | TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY(TAPESTRY) | recruiting | N/A | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05688176 | Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers | recruiting | — | 100 | University Hospital, GhentOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer | recruiting | Phase 3 | 436 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06413342 | Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 191 | Zhejiang Cancer HospitalOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06339060 | An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).(PALACE3) | recruiting | Phase 3 | 356 | Ruijin HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06385730 | Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)(BLESS) | recruiting | Phase 2 | 60 | Shanghai Chest HospitalOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06084897 | Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy | recruiting | Phase 2 | 120 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | recruiting | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06431100 | a Single-arm, Single-center, Open Clinical Study(GK-01) | recruiting | — | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06408584 | Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab(SCHRT) | recruiting | — | 25 | Anhui Provincial HospitalOTHER_GOV | 1 | May 21, 2024 | clinicaltrials |
| NCT06410651 | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | recruiting | Phase 3 | 354 | Fudan UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06385717 | Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer(ESCORT) | recruiting | — | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06361043 | Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)(ARTEC) | recruiting | — | 30 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06304350 | Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Tongji UniversityOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06187597 | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)(EC-CRT-007) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04455282 | CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1(CIRCULATE1) | recruiting | — | 100 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02454790 | Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer(SFP OES) | recruiting | — | 10,000 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04886635 | Surgery As Needed for Oesophageal Cancer - 2(SANO-2) | recruiting | — | 360 | Bas P. L. WijnhovenOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03222895 | Distribution of Lymph Node Metastases in Esophageal Carcinoma(TIGER) | recruiting | — | 5,000 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 14 | Feb 13, 2024 | clinicaltrials |
| NCT05967910 | The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)(STRESS-ESCA) | recruiting | — | 200 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02735057 | Chemoradiotherapy in Elderly Patients With Oesophagus Cancer(OSAGE) | recruiting | Phase 1 / Phase 2 | 54 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06189898 | Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study(FIRASE) | recruiting | — | 48 | Sebastian ZschaeckOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05833594 | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06136845 | The Correlation Between Microbiome of Esophageal Cancer Patients and Post Esophagectomy Anastomotic Leaks(microbiome) | recruiting | — | 300 | Rambam Health Care CampusOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05624099 | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | recruiting | Phase 2 | 75 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03964753 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma(NTNC) | recruiting | Phase 2 | 202 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06056336 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 73 | Guo XufengOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06037902 | CPAP for Esophageal Cancer With Radiotherapy(TROS-7) | recruiting | N/A | 44 | Sheba Medical CenterOTHER_GOV | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05952661 | Minimally Residual of Esophageal Cancer 001(ECMRD-001) | recruiting | — | 56 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05443841 | Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)(ECTOP-2005) | recruiting | — | 385 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05800054 | Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer | recruiting | N/A | 210 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 29, 2024source: clinicaltrials